Invasive mold disease in thoracic organ transplant recipients is a well-recognized complication, but the long-term persistence of molds within the human body and evasion of host defenses has not been well-described. We present 2 cases of invasive mold disease (Verruconis gallopava and Aspergillus fumigatus) in thoracic transplant recipients who had the same mold cultured years prior to the invasive disease presentation. The paired isolates from the index and recurrent infections in both patients were compared using whole-genome sequencing to determine if the same strain of mold caused both the index and recurrent infections. In Case 1, the isolates were found to be of the same strain indicating that the initial colonizing isolate identified pre-transplant eventually caused invasive mold disease post-transplant while in Case 2, the 2 isolates were not of the same strain. These results demonstrate the distinct possibility of molds both persisting within the human body for years prior to invasive mold disease or the long-term risk of recurrent, persistent infection with more than one strain. Further studies of long-term molecular epidemiology of IMD and risk factors for mold persistence in transplant recipients are encouraged.
| INTRODUC TI ON
Invasive mold disease (IMD) is relatively common in patients who have undergone thoracic solid organ transplantation. For instance, invasive aspergillosis occurs at rates reported between 6.5% and 14% in orthotopic heart transplant recipients. 1, 2 Within the lung transplant population, IMD has been reported in up to 12% of patients, with Aspergillus species being the major pathogen (72.7%). 3 In the case of aspergillosis, immunosuppressive therapies for solid organ transplantation increase the risk of IMD by inhibiting T-cell activation and response to cytokines, hindering host defense to Aspergillus species at multiple levels. 4 Theoretically, the risk of recurrent or persistent IMD continues as ongoing immunosuppressive therapy is vital for maintaining the longevity of the allograft.
However, the persistence of invasive fungal infection with molds is not as well documented as with cryptococcosis and the endemic mycoses.
While we have insight into clinical (host) risk factors for IMD, we are still learning about the microorganism's ability to adapt and persist within the human body. This adaptation likely involves a combination of physiologic and genetic events. 5 Next-generation sequencing of mold isolates can provide precise insights into the genetic identification and adaptation of the mold within the body.
For instance, it can determine whether the same strain of mold can persist for years in the host and then cause recurrent disease. Here, we present 2 cases of thoracic organ transplant recipients who were known to have respiratory mold colonization followed by invasive disease due to the same mold species many years later.
| Case 1
A 65-year-old man with a history of Hodgkin's lymphoma, a 30- The patient was treated with voriconazole for suspicion of IMD due to Verruconis. Unfortunately, he suffered septic shock from a healthcare-associated pneumonia thought not to be directly related to IMD and passed away 6 weeks later.
| Case 2
In 2014, a 61-year-old man with ischemic cardiomyopathy sta- 
| MATERIAL S AND ME THODS
Paired mold isolates from each patient were retrieved from our clini- Additional methods for DNA extraction and whole-genome sequencing can be found in Data S1.
| RE SULTS
For the patient with invasive Verruconis (Case 1), the isolates were predicted to be of the same strain indicating that the initial colonizing isolate pre-lung transplant eventually, despite several courses Compared to the reference genome, both isolates contained a predicted missense variant (V65A) in the cyp51a gene (PV09_06865), which is the target of azole binding. However, this change is unlikely to increase drug resistance as it is a conservative change, and the isolate phenotypically did not appear to be resistant to azoles in vitro.
In the patient with recurrent invasive aspergillosis (Case 2), the 2 isolates were not genetically related. Each of the 2 isolates dif- 
| D ISCUSS I ON
We present 2 challenging cases of IMD in thoracic transplant recipients including the first report of relapsed infection due to V. gallopava resulting in an invasive transglottic mass and a cardiac device infection due to A. fumigatus. Whole-genome sequencing was utilized to precisely determine if this was due to persistence of the same fungal strain. In Case 1, the strains of Verruconis were essentially the same, but in Case 2, the strains of Aspergillus were different. In the second case, the mold infection was either secondary to a new or recurrent strain. However, in Case 1, the mold progressed from colonization to disease despite voriconazole treatment as the patient experienced augmentation of immunosuppression for treatment of rejection.
One possible explanation of how a mold can cause recurrent infection or even persist within the host for years is the concept of adaptation. Adaptation is defined by a microorganism's ability to change its phenotype to improve its fitness when challenged by new environmental conditions. 5 It is postulated to occur within a spectrum of 4 events: (1) Aspergillus, in particular, possesses a biochemical versatility that allows adaptation within its environments and may result in fungal persistence within the host. 7 Additionally, its genome encodes virulence factors, azole resistance mechanisms, and cell wall modifications that allow the mold to evade the host's immune system and antifungal therapy. [7] [8] [9] Another study of serial A. fumigatus isolates from patients noted a non-synonymous mutation in the cyp51A
gene of an itraconazole-resistant isolate as previously noted by targeted sequencing. 10, 11 We did not observe non-synonymous mutations in cyp51A or cyb51b in the 2 collected isolates in this study that match known resistance mutations, consistent with the lack of measured azole resistance in vitro. 10 In Case 2, we hypothesize that this patient suffered from a chronic, Biofilms are formed when microorganisms attach irreversibly to the surface of an anatomic site or medical device, grow, and produce extracellular polymers to facilitate matrix formation. 12 The formation of an extracellular matrix can alter the organism's phenotype by modifying growth rate and gene transcription, leading to decreased antimicrobial susceptibility. For example, within bronchial epithelial biofilms and among the A. fumigatus isolates persisting in these biofilms, MICs to voriconazole, posaconazole, and itraconazole were noted to increase from a range of 0.125-0.25 g/mL to 1-2 g/ mL. 13 The suspicion for biofilm formation and previous exposure to triazoles therapy in Case 2 prompted azole susceptibility testing on the second A. fumigatus strain. The MIC was 0.25 μg/mL, which was relatively susceptible, and this functional assay was supported by the whole-genome sequencing analysis. Although there were nonsynonymous sequence changes in the ERG11 gene (cyp51A) that is the target of azole drugs, there were no changes in the positions that have been associated with drug resistance.
Previous cases of A. fumigatus cardiac device infection have been reported in the literature with diagnosis ranging from 2 to 7 years post-device implantation. 14, 15 Similar to Case 1, these published cases were associated with a delay in diagnosis likely due to the rarity of this pathogen causing cardiac device infection. Regardless of pathology, particularly in an immunosuppressed host, late cardiac device infection due to Aspergillus should be considered in the differential diagnosis due to the mold's ability to smolder within a biofilm on hardware for many years as demonstrated by Case 2.
In contrast to Aspergillus, less is known about the epidemiology and pathogenesis of V. gallopava. It is a dematiaceous, thermotolerant mold that causes zoonotic and human infection with a predilection for central nervous system invasion. In humans, it tends to infect immunocompromised hosts likely through inhalation of spores with the potential for extrapulmonary dissemination. 16 In a series of 10
cases from the University of Pittsburgh, investigators report that all cases occurred in solid organ transplant recipients, and most occurred late after transplantation with pulmonary manifestations. 17 The attributable 6-month mortality rate was 20%. In our case, this mold likely colonized the patient's airway for years prior to becoming an invasive mold at the site of colonization during the iatrogenic immunosuppression. In fact, azole preemptive therapy did not seem to eliminate this mold unless the patient was re-infected from a similar environmental source over time, which seemed unlikely.
In reporting these cases with a corresponding whole-genome sequencing investigation, we hope that other providers will recognize that molds can persist within the immunosuppressed host for years (Case 1) and cause invasive disease in the setting of augmentation of immunosuppression. Conversely, invasive mold disease can recur due to a re-infection event in a chronically immunosuppressed host or lay dormant within a biofilm for years (Case 2). We envision a larger study would need to encompass a long period of time to capture these events (in Case 1, up to 10 years) and characterize which mold species can cause persistent or recurrent disease. Use of next-generation sequencing techniques will help elucidate the molecular epidemiology of these pathogens and can precisely document infecting strains that evade host immune defenses.
As we do not know the mutation rate for these mold species within the host, we cannot declare the precise number of SNPs required to per base per generation. 18 Furthermore, our work with serial isolates of Cryptococcus suggested that the mutation rate of this yeast in the cerebrospinal fluid of the human host was approximately one polymorphism change every 58 days. 6 Interpreting our results for the Aspergillus cases based on these data, it is likely that the difference of 18 368 SNPs would require a mutation rate that is many orders of magnitude higher than those estimated for other fungi, so the Aspergillus infection would be inconsistent with a clonal infection in our opinion.
In conclusion, we report 2 cases of unusual manifestations of IMD in thoracic organ transplant recipients and characterize how molds can persist within the human body with use of whole genome sequencing.
Whilst we cannot draw conclusions on optimal treatment of these infections, we suspect that Case 2 achieved cure with a combination of surgical resection of the pacemaker lead and prolonged antifungal therapy. Case 1's IMD was likely being controlled with antifungal therapy at the time of his death, but assurance of cure could not be determined. Finally, with more sequencing data from infecting strains and quantitative measurement of clinically important phenotypes, we might be able to find a molecular blueprint of this mechanism. We also need ways to catalog and validate mutations that cause drug resistance, particularly in fungi like V. gallopava that are not widely studied.
It is clear that fungi will microevolve to persist within the host, and we now have the molecular tools to provide a window into this process.
